Dhanuka Agritech Q3 Profit Plunges 27%, Management Cries 'Bad Phase Over'

AGRICULTURE
Whalesbook Logo
AuthorSatyam Jha|Published at:
Dhanuka Agritech Q3 Profit Plunges 27%, Management Cries 'Bad Phase Over'
Overview

Dhanuka Agritech reported a challenging Q3 FY26 with revenue falling 7.94% YoY to ₹409.92 crore and Profit After Tax (PAT) down 27.33% to ₹40 crore. EBITDA also declined 22.37%. The company cited industry-wide demand stress due to adverse weather and low crop prices. Despite the downturn, management expressed confidence that the 'bad phase is over' and is focusing on rural penetration, new products, and international expansion for a long-term double-digit CAGR.

📉 The Financial Deep Dive

The Numbers: Dhanuka Agritech posted a subdued third quarter for FY26. Revenue from operations stood at ₹409.92 crore, a year-on-year decrease of 7.94% from ₹445.27 crore in Q3 FY25. Profitability took a sharper hit, with EBITDA declining 22.37% YoY to ₹58.66 crore from ₹75.56 crore. Consequently, the EBITDA margin compressed to 14.31% from 16.97% in the prior year. Profit After Tax (PAT) saw a 27.33% fall, reaching ₹40 crore compared to ₹55.04 crore in Q3 FY25. Basic Earnings Per Share (EPS) also decreased by 27.59% to ₹8.87 from ₹12.25.

The Quality: The margin compression is evident, with EBITDA margins falling by approximately 266 basis points YoY. The steeper decline in PAT compared to revenue suggests impact from operating leverage or potential cost pressures. The company also highlighted a ₹15 crore sales impact in Q3 FY26 due to regulatory challenges for biostimulant products.

Management Commentary & Outlook: Management attributed the weak performance to broad industry challenges, including stressed demand drivers, adverse weather, low crop prices, and delayed farmer purchases, particularly affecting South and West India. Despite these headwinds, the company expressed optimism, stating that the "bad phase is over" and assuring stakeholders of a future turnaround. The strategic focus remains on rural market penetration, new product introductions, technical manufacturing, and international market expansion, with a long-term target of a double-digit CAGR.

The company reported successful commercialization of a second product from its Dahej plant in Q3 FY26 and aims to achieve EBITDA positive operations at Dahej by FY27, targeting 80% capacity utilization. The business plan for MPP-2 is nearing completion, with an estimated CAPEX of ₹60-70 crore. Regulatory approvals for new biostimulant offerings are expected by the end of Q4 FY26, with a launch planned for Q1 FY27. Integration of two Bayer molecules is progressing, contributing ₹25-27 crore to the topline in 9MFY26.

For the full fiscal year FY26, management anticipates flattish revenue growth. The company is developing three new product launches for FY27. Discussions for potential collaborations at the Dahej plant with Japanese and European companies are ongoing.

Risks & Forward View: Key risks include continued demand weakness, adverse weather patterns impacting agricultural output, and execution challenges in ramping up Dahej plant operations and launching new products. Regulatory hurdles for biostimulants, though expected to be resolved, have impacted sales. Investors will monitor the company's ability to navigate these industry-specific challenges and deliver on its turnaround strategy. The successful ramp-up of the Dahej facility and the timely launch of new products in FY27 will be crucial catalysts for future growth.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.